Compare RRX & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RRX | DVA |
|---|---|---|
| Founded | 1955 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Misc Health and Biotechnology Services |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1B | 14.9B |
| IPO Year | 1994 | 2003 |
| Metric | RRX | DVA |
|---|---|---|
| Price | $154.18 | $186.65 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 8 |
| Target Price | ★ $231.10 | $219.86 |
| AVG Volume (30 Days) | ★ 1.0M | 573.5K |
| Earning Date | 11-03-2026 | 10-28-2026 |
| Dividend Yield | ★ 0.90% | N/A |
| EPS Growth | ★ 42.86 | N/A |
| EPS | 2.71 | ★ 6.86 |
| Revenue | $3,257,100,000.00 | ★ $13,643,069,000.00 |
| Revenue This Year | $4.41 | $3.77 |
| Revenue Next Year | $14.07 | $3.39 |
| P/E Ratio | $57.61 | ★ $27.57 |
| Revenue Growth | 5.21 | ★ 6.46 |
| 52 Week Low | $127.96 | $101.00 |
| 52 Week High | $247.80 | $247.49 |
| Indicator | RRX | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 41.36 | 57.35 |
| Support Level | $145.98 | $186.61 |
| Resistance Level | $168.16 | $202.63 |
| Average True Range (ATR) | 5.44 | 3.78 |
| MACD | 0.16 | 1.47 |
| Stochastic Oscillator | 19.73 | 82.52 |
Regal Rexnord Corp is in the engineering and manufacturing of industrial powertrain solutions, power transmission components, electric motors, electronic controls, air-moving products, and specialty electrical components and systems, serving customers around the world. The three operating segments include Automation & Motion Control (AMC) segment; Industrial Powertrain Solutions (IPS) segment, which derives maximum revenue; and Power Efficiency Solutions (PES) segment. Geographically, the company operates in North America, Europe, Asia, and Rest of the world, of which it derives maximum revenue from North America.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.